HONG KONG – Osaka, Japan-based Ono Pharmaceutical Co. Ltd. entered a license agreement with Bristol-Myers Squibb Co. for the development and commercialization of its compound, ONO-4578, a selective antagonist of EP4, a prostaglandin E2 (PGE2) receptor. An oral antagonist of EP4 developed using mouse models, ONO-4578 has showed an antitumor effect by improving immunosuppressive tumor microenvironment, and Ono already started a phase I study of the compound in Japan.
HONG KONG – Enleofen Bio Pte Ltd., of Singapore, said it has discovered a key target for the treatment of fibrosis, which could significantly improve the therapies by offering more effective options with fewer side effects to the patients.
HONG KONG – Enleofen Bio Pte Ltd., of Singapore, said it has discovered a key target for the treatment of fibrosis, which could significantly improve the therapies by offering more effective options with fewer side effects to the patients.
HONG KONG – In a pivotal phase III study, Tokyo-based Daiichi Sankyo Co. Ltd.'s pexidartinib met its primary endpoint of tumor response, measured by size reduction, in patients with symptomatic tenosynovial giant cell tumor (TGCT).
HONG KONG – With a series of advancements in the area of biosimilar development, China’s Shanghai Fosun Pharmaceutical Group Co. Ltd. is getting closer to becoming the first domestic company to market a biosimilar product in China.
HONG KONG – In a pivotal phase III study, Tokyo-based Daiichi Sankyo Co. Ltd.'s pexidartinib met its primary endpoint of tumor response, measured by size reduction, in patients with symptomatic tenosynovial giant cell tumor (TGCT).
HONG KONG – Established in February, South Korean biotech startup Bionetix Inc. has already secured a partnership with Southern Research to develop cancer drugs, and plans to move into the clinic with a lead program targeting glaucoma in 2019.
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) and Astrazeneca plc released positive preliminary safety and anti-tumor activity data of co-developed potential first-in-class inhibitor savolitinib in combination with other immunotherapy agents from two phase Ib/II experiments.
HONG KONG – Established in February, South Korean biotech startup Bionetix Inc. has already secured a partnership with Southern Research to develop cancer drugs, and plans to move into the clinic with a lead program targeting glaucoma in 2019.
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) and Astrazeneca plc released positive preliminary safety and anti-tumor activity data of co-developed potential first-in-class inhibitor savolitinib in combination with other immunotherapy agents from two phase Ib/II experiments.
